IDH2 (P48735) variants and mutations
IDH2 (also known as P48735) is a human protein-coding gene encoding an isocitrate dehydrogenase [NADP], mitochondrial protein. It normally generates alpha-ketoglutarate and NADPH inside mitochondria. Recurrent R140 and R172 cancer-associated variants instead produce D-2-hydroxyglutarate, an oncometabolite that drives epigenetic dysregulation in acute myeloid leukemia and other tumors. This analysis covers 1,082 IDH2 variants and mutations. Of these, 65% have computational variant effect predictions. Disease context includes D-2-hydroxyglutaric aciduria, glioma, and acute myeloid leukemia. Example IDH2 variants include A2G, A2T, and G3D.
Variant analysis overview
- Gene: IDH2
- Protein: P48735
- UniProt accession: P48735
- Organism: Homo sapiens
- Variants analyzed: 1082
- Variant scope: all variants
- Completed: 2026-08-18
Variant and mutation evidence
- Variant composition: 861 unspecified-consequence records; 1 stop lost; 1 stop retained variant; 10 frameshift variants; 109 missense variants; 88 synonymous variants; 4 in-frame deletions; 3 stop-gained variants; 4 splice-region variants; 1 substitution
- Prediction scores: 699 variants have prediction scores (65% of the analyzed set).
Clinical, disease, and population context
- Disease context: 25 disease associations are represented. Top associations: D-2-hydroxyglutaric aciduria, glioma, acute myeloid leukemia, astrocytoma (excluding glioblastoma), 2-hydroxyglutaric aciduria, oligodendroglioma, myeloid neoplasm, myeloid leukemia, myelodysplastic syndrome, Maffucci syndrome, hereditary disease, angioimmunoblastic T-cell lymphoma.
Protein structure and variant hotspots
- Protein features: 11 binding sites; 29 post-translational modification sites.
- PTM context: 33 variants overlap post-translational modification sites.
Data sources
Evidence in this analysis draws on EBI Proteins Variation, UniProt, gnomAD v4, EuropePMC, 3D Hotspot Analysis, Interaction Network Analysis, Protein Data Bank, AlphaFold DB, gnomAD constraint, Open Targets, MaveDB, LitVar.
Notable IDH2 variants
Examples include A2G, A2T, G3D, G3R, G3V, Y4S, L5P, L5Q. Listed records include available protein-change notation, database identifiers, clinical classifications, computational predictions, population evidence, experimental measurements, and disease context.
- A2G (p.Ala2Gly), rs2505812059, ClinGen CA393803769, ClinVar RCV003236024, REVEL 0.36, CADD 21.40, Uncertain significance, not provided
- A2T (p.Ala2Thr), Ensembl rs2151558099, REVEL 0.40, CADD 20.80
- G3D (p.Gly3Asp), ExAC rs754014307, TOPMed rs754014307, gnomAD rs754014307, REVEL 0.53, CADD 24.00, Uncertain significance, D-2-hydroxyglutaric aciduria 2
- G3R (p.Gly3Arg), ExAC rs755082688, gnomAD rs755082688, REVEL 0.44, CADD 23.00
- G3V (p.Gly3Val), ExAC rs754014307, TOPMed rs754014307, gnomAD rs754014307, REVEL 0.50, CADD 22.80
- Y4S (p.Tyr4Ser), Ensembl rs2151558092, REVEL 0.38, CADD 23.80
- L5P (p.Leu5Pro), ExAC rs766605461, gnomAD rs766605461, REVEL 0.54, CADD 29.80
- L5Q (p.Leu5Gln), ExAC rs766605461, gnomAD rs766605461, REVEL 0.52, CADD 28.60
- L5V (p.Leu5Val), TOPMed rs1901360602, REVEL 0.38, CADD 26.20
- R6W (p.Arg6Trp), 1000Genomes rs549177872, ExAC rs549177872, TOPMed rs549177872, gnomAD rs549177872, REVEL 0.48, CADD 24.80, Benign
- V7A (p.Val7Ala), Ensembl rs1596083355, REVEL 0.13, CADD 14.40
- V7I (p.Val7Ile), NCI-TCGA TCGA novel, REVEL 0.10, CADD 15.60, Variant assessed as somatic; moderate impact.
- V8A (p.Val8Ala), rs369445642, ClinGen CA7733298, cosmic curated COSV57478, ClinVar RCV000676986, REVEL 0.10, CADD 10.20, Conflicting interpretations, D-2-hydroxyglutaric aciduria 2; not provided
- V8E (p.Val8Glu), 1000Genomes rs369445642, ESP rs369445642, ExAC rs369445642, TOPMed rs369445642, REVEL 0.34, CADD 18.10, Likely benign
- V8G (p.Val8Gly), 1000Genomes rs369445642, ESP rs369445642, ExAC rs369445642, TOPMed rs369445642, REVEL 0.16, CADD 18.10, Likely benign
- V8L (p.Val8Leu), gnomAD rs1328301039, REVEL 0.15, CADD 11.00
- V8M (p.Val8Met), gnomAD rs1328301039, REVEL 0.10, CADD 16.40
- R9G (p.Arg9Gly), Ensembl rs1596083346, REVEL 0.30, CADD 23.00
- R9H (p.Arg9His), Ensembl rs2151558074, REVEL 0.15, CADD 23.20
- R9S (p.Arg9Ser), Ensembl rs1596083346, REVEL 0.10, CADD 18.60
- S10L (p.Ser10Leu), rs1234438811, ClinGen CA393803725, ClinVar RCV002035774, TOPMed rs1234438811, REVEL 0.34, CADD 22.20, Uncertain significance, D-2-hydroxyglutaric aciduria 2
- L11R (p.Leu11Arg), TOPMed rs1258065873, REVEL 0.47, CADD 22.10
- C12G (p.Cys12Gly), TOPMed rs1338052183, REVEL 0.14, CADD 15.20
- C12Y (p.Cys12Tyr), Ensembl rs2151558066, REVEL 0.19, CADD 13.90
- R13I (p.Arg13Ile), ExAC rs763654597, TOPMed rs763654597, gnomAD rs763654597, REVEL 0.22, CADD 15.00
- R13K (p.Arg13Lys), ExAC rs763654597, TOPMed rs763654597, gnomAD rs763654597, REVEL 0.09, CADD 9.07
- A14G (p.Ala14Gly), Ensembl rs1901359001
- A14S (p.Ala14Ser), cosmic curated COSV57473, Ensembl rs1901359085, REVEL 0.13, CADD 17.30
- S15P (p.Ser15Pro), Ensembl rs2151558055, REVEL 0.18, CADD 15.50
- G16D (p.Gly16Asp), rs775225193, ClinGen CA7733294, ClinVar RCV002511804, ClinVar RCV003164758, REVEL 0.17, CADD 14.70, Uncertain significance, not provided; Inborn genetic diseases; D-2-hydroxyglutaric aciduria 2
- G16S (p.Gly16Ser), ExAC rs762573949, TOPMed rs762573949, gnomAD rs762573949, REVEL 0.16, CADD 13.90
- S17L (p.Ser17Leu), gnomAD rs1396836085, REVEL 0.17, CADD 17.20
- S17W (p.Ser17Trp), gnomAD rs1396836085, REVEL 0.33, CADD 22.10
- R18Q (p.Arg18Gln), TOPMed rs1453618042, gnomAD rs1453618042, REVEL 0.09, CADD 15.90, Uncertain significance, Inborn genetic diseases
- R18W (p.Arg18Trp), ExAC rs769572350, gnomAD rs769572350, REVEL 0.22, CADD 20.90
- P19L (p.Pro19Leu), ExAC rs745652382, gnomAD rs745652382, REVEL 0.09, CADD 15.50
- P19R (p.Pro19Arg), ExAC rs745652382, gnomAD rs745652382, REVEL 0.09, CADD 15.90
- A20S (p.Ala20Ser), NCI-TCGA TCGA novel, REVEL 0.14, CADD 11.60, Variant assessed as somatic; moderate impact.
- A20T (p.Ala20Thr), Ensembl rs2151558035, REVEL 0.14, CADD 15.00
- W21* (p.Trp21Ter), rs776341694, ClinGen CA393803624, ClinVar RCV003842530, ExAC rs776341694, CADD 25.90, Uncertain significance
- W21S (p.Trp21Ser), rs776341694, ClinGen CA7733291, ClinVar RCV001817315, ClinVar RCV003514529, REVEL 0.20, CADD 19.20, Uncertain significance, not specified; D-2-hydroxyglutaric aciduria 2; Inborn genetic diseases
- A22S (p.Ala22Ser), gnomAD rs1282863956, REVEL 0.13, CADD 14.50
- A22T (p.Ala22Thr), gnomAD rs1282863956, REVEL 0.13, CADD 17.90
- A22V (p.Ala22Val), rs770871840, ClinGen CA7733290, ClinVar RCV002034001, ExAC rs770871840, REVEL 0.13, CADD 20.40, Uncertain significance, D-2-hydroxyglutaric aciduria 2
- P23A (p.Pro23Ala), TOPMed rs1433340280, gnomAD rs1433340280, REVEL 0.18, CADD 17.80, Uncertain significance
- P23R (p.Pro23Arg), rs746881165, ClinGen CA7733289, ClinVar RCV002024420, 1000Genomes rs746881165, REVEL 0.20, CADD 23.40, Uncertain significance, D-2-hydroxyglutaric aciduria 2
- P23S (p.Pro23Ser), rs1433340280, ClinGen CA393803606, ClinVar RCV002225999, TOPMed rs1433340280, REVEL 0.18, CADD 22.50, Uncertain significance, not provided
- A24V (p.Ala24Val), ExAC rs777789880, gnomAD rs777789880, REVEL 0.13, CADD 19.00
- A25D (p.Ala25Asp), TOPMed rs1371083762, gnomAD rs1371083762, REVEL 0.13, CADD 22.60
- A25G (p.Ala25Gly), TOPMed rs1371083762, gnomAD rs1371083762, REVEL 0.08, CADD 19.30
- A25V (p.Ala25Val), cosmic curated COSV10521, TOPMed rs1371083762, gnomAD rs1371083762, REVEL 0.08, CADD 18.60
- L26P (p.Leu26Pro), gnomAD rs1212451541, REVEL 0.13, CADD 18.60
- T27A (p.Thr27Ala), Ensembl rs2151558015, REVEL 0.05, CADD 13.10
- T27P (p.Thr27Pro), Ensembl rs2151558015
- T27S (p.Thr27Ser), Ensembl rs2151558015, REVEL 0.06, CADD 12.00
- A28S (p.Ala28Ser), TOPMed rs1901356514, REVEL 0.10, CADD 5.02
- A28T (p.Ala28Thr), rs1901356514, ClinGen CA393803551, ClinVar RCV004397853, REVEL 0.11, CADD 10.50, Uncertain significance, Inborn genetic diseases
- A28V (p.Ala28Val), TOPMed rs1317679019, gnomAD rs1317679019, REVEL 0.09, CADD 13.70
- P29A (p.Pro29Ala), Ensembl rs1431694926, REVEL 0.05, CADD 10.90
- P29L (p.Pro29Leu), gnomAD rs1315214325, REVEL 0.14, CADD 19.90
- T30P (p.Thr30Pro), gnomAD rs1435460437, Uncertain significance
- T30S (p.Thr30Ser), rs1435460437, ClinGen CA393803527, ClinVar RCV002595726, gnomAD rs1435460437, REVEL 0.08, CADD 8.64, Uncertain significance, D-2-hydroxyglutaric aciduria 2
- S31P (p.Ser31Pro), Ensembl rs2151558000, REVEL 0.17, CADD 18.50
- Q32P (p.Gln32Pro), TOPMed rs1377173957, gnomAD rs1377173957, REVEL 0.18, CADD 14.80, Uncertain significance, Inborn genetic diseases
- E33G (p.Glu33Gly), rs2151557992, ClinGen CA393803488, ClinVar RCV001768544, Ensembl rs2151557992, REVEL 0.15, CADD 22.30, Uncertain significance, not provided
- E33K (p.Glu33Lys), gnomAD rs1171749840, REVEL 0.14, CADD 19.30
- Q34* (p.Gln34Ter), Ensembl rs2151557989, CADD 39.00
- P35A (p.Pro35Ala), TOPMed rs1901355459, REVEL 0.13, CADD 16.40
- P35L (p.Pro35Leu), TOPMed rs886385060, REVEL 0.10, CADD 21.90
- P35Q (p.Pro35Gln), rs886385060, ClinGen CA393803463, ClinVar RCV003513937, REVEL 0.13, CADD 18.40, Uncertain significance, D-2-hydroxyglutaric aciduria 2
- P35S (p.Pro35Ser), TOPMed rs1901355459, REVEL 0.13, CADD 17.30
- R36L (p.Arg36Leu), ExAC rs780252226, gnomAD rs780252226, REVEL 0.34, CADD 23.60
- R36P (p.Arg36Pro), ExAC rs780252226, gnomAD rs780252226, REVEL 0.38, CADD 23.80
- R37C (p.Arg37Cys), rs1567261734, ClinGen CA393803447, ClinVar RCV002038981, NCI-TCGA TCGA novel, REVEL 0.45, CADD 32.00, Uncertain significance, D-2-hydroxyglutaric aciduria 2
- R37H (p.Arg37His), cosmic curated COSV10609, TOPMed rs1005767629, gnomAD rs1005767629, REVEL 0.35, CADD 27.00, Uncertain significance, D-2-hydroxyglutaric aciduria 2
- R37S (p.Arg37Ser), Ensembl rs1567261734, REVEL 0.32, CADD 23.40, Uncertain significance
- H38L (p.His38Leu), Ensembl rs2151557972, REVEL 0.14, CADD 18.90
- H38P (p.His38Pro), Ensembl rs2151557972
- A40S (p.Ala40Ser), cosmic curated COSV57474, Ensembl rs2151551874
- A40V (p.Ala40Val), NCI-TCGA TCGA novel, Ensembl rs2151551873, REVEL 0.28, CADD 23.70, Variant assessed as somatic; moderate impact.
- D41E (p.Asp41Glu), NCI-TCGA TCGA novel, REVEL 0.13, CADD 18.10, Variant assessed as somatic; moderate impact.
- D41N (p.Asp41Asn), rs372928432, ClinGen CA7733275, ClinVar RCV002779278, ESP rs372928432, REVEL 0.11, CADD 17.00, Uncertain significance, Inborn genetic diseases
- K42E (p.Lys42Glu), Ensembl rs758194887, REVEL 0.15, CADD 21.00
- K42R (p.Lys42Arg), gnomAD rs1901039396, REVEL 0.14, CADD 20.30
- R43G (p.Arg43Gly), Ensembl rs2151551866
- R43S (p.Arg43Ser), TOPMed rs988769536, gnomAD rs988769536, REVEL 0.36, CADD 23.50
- V46E (p.Val46Glu), rs1418340668, ClinGen CA393803092, ClinVar RCV001036393, TOPMed rs1418340668, REVEL 0.79, CADD 27.40, Uncertain significance, D-2-hydroxyglutaric aciduria 2
- V46G (p.Val46Gly), TOPMed rs1418340668, gnomAD rs1418340668, REVEL 0.79, CADD 29.50, Uncertain significance
- A47G (p.Ala47Gly), ExAC rs201173543, TOPMed rs201173543, gnomAD rs201173543, Uncertain significance
- A47V (p.Ala47Val), rs201173543, ClinGen CA7733273, NCI-TCGA Cosmic COSV5748, cosmic curated COSV57480, REVEL 0.20, CADD 22.40, Uncertain significance, D-2-hydroxyglutaric aciduria 2
- K48N (p.Lys48Asn), ExAC rs773071883, gnomAD rs773071883, REVEL 0.10, CADD 17.50
- P49A (p.Pro49Ala), rs1164126819, ClinGen CA393803077, ClinVar RCV002462529, ClinVar RCV003103132, AlphaMissense 0.42, MetaLR 0.57, Uncertain significance, D-2-hydroxyglutaric aciduria 2; not provided
- P49S (p.Pro49Ser), TOPMed rs1164126819, gnomAD rs1164126819, REVEL 0.45, AlphaMissense 0.42
- V50M (p.Val50Met), rs201999104, ClinGen CA7733268, cosmic curated COSV57473, ClinVar RCV003075253, REVEL 0.73, CADD 25.50, Uncertain significance, D-2-hydroxyglutaric aciduria 2
- V51L (p.Val51Leu), gnomAD rs1901038186, REVEL 0.76, CADD 26.30
- E52* (p.Glu52Ter), cosmic curated COSV57484, ExAC rs769970669, gnomAD rs769970669, CADD 39.00
- G55D (p.Gly55Asp), rs868324434, []
- M58L (p.Met58Leu), Ensembl rs2151551841
- M58R (p.Met58Arg), ExAC rs746033152, TOPMed rs746033152, gnomAD rs746033152, REVEL 0.86, CADD 29.00, Uncertain significance, Inborn genetic diseases
- T59I (p.Thr59Ile), TOPMed rs1901037718, gnomAD rs1901037718
- T59S (p.Thr59Ser), TOPMed rs1901037718, gnomAD rs1901037718, REVEL 0.82, CADD 26.80
- R60C (p.Arg60Cys), NCI-TCGA Cosmic COSV5747, NCI-TCGA Cosmic COSV5748, cosmic curated COSV57482, Ensembl rs1596076730, REVEL 0.88, CADD 29.10, Variant assessed as somatic; moderate impact.
- R60G (p.Arg60Gly), cosmic curated COSV57472, Ensembl rs1596076730
- R60H (p.Arg60His), ExAC rs757504997, TOPMed rs757504997, gnomAD rs757504997, REVEL 0.74, CADD 25.20, Uncertain significance, D-2-hydroxyglutaric aciduria 2
- W63* (p.Trp63Ter), cosmic curated COSV57468, Ensembl rs2151551823
- Q64* (p.Gln64Ter), Ensembl rs2151551820
- F65Y (p.Phe65Tyr), Ensembl rs1901037000
- K67R (p.Lys67Arg), ExAC rs759030336, gnomAD rs759030336, REVEL 0.44, CADD 24.30
- K67T (p.Lys67Thr), ExAC rs759030336, gnomAD rs759030336, REVEL 0.83, CADD 29.70
- E68D (p.Glu68Asp), Ensembl rs2151551808
- E68G (p.Glu68Gly), gnomAD rs1901036665, REVEL 0.82, CADD 29.00
- E68K (p.Glu68Lys), cosmic curated COSV10463, TOPMed rs1209495241, gnomAD rs1209495241, REVEL 0.66, CADD 23.40
- K69E (p.Lys69Glu), rs1299878535, ClinGen CA393802935, ClinVar RCV002902770, TOPMed rs1299878535, REVEL 0.48, CADD 24.80, Uncertain significance, Inborn genetic diseases
- I71T (p.Ile71Thr), Ensembl rs1405190167
- L72R (p.Leu72Arg), Ensembl rs2151551355, REVEL 0.53, CADD 25.20
- H74Y (p.His74Tyr), rs1163791289, NCI-TCGA Cosmic COSV1003, cosmic curated COSV10034, TOPMed rs1163791289, AlphaMissense 0.07, MetaLR 0.06, Variant assessed as somatic; moderate impact.
- V75E (p.Val75Glu), Ensembl rs2151551343
- V75M (p.Val75Met), rs956543166, ClinGen CA274626635, ClinVar RCV001897577, TOPMed rs956543166, REVEL 0.49, CADD 24.40, Uncertain significance, D-2-hydroxyglutaric aciduria 2
- D76G (p.Asp76Gly), rs1901009838, ClinGen CA393802877, ClinVar RCV001233032, Ensembl rs1901009838, AlphaMissense 0.41, MetaLR 0.62, Uncertain significance, D-2-hydroxyglutaric aciduria 2
- D76H (p.Asp76His), Ensembl rs2151551340
- D76Y (p.Asp76Tyr), Ensembl rs2151551340
- I77M (p.Ile77Met), TOPMed rs866778992
- I77V (p.Ile77Val), Ensembl rs1596076154
- Q78L (p.Gln78Leu), Ensembl rs2151551333
- L79V (p.Leu79Val), gnomAD rs1194618510, REVEL 0.35, CADD 23.20
- Y81C (p.Tyr81Cys), gnomAD rs1251356293
- Y81N (p.Tyr81Asn), TOPMed rs1455889466, gnomAD rs1455889466, REVEL 0.74, CADD 29.60
- F82V (p.Phe82Val), ExAC rs765936488, TOPMed rs765936488, gnomAD rs765936488, REVEL 0.71, CADD 28.60
- D83E (p.Asp83Glu), ExAC rs760427398, gnomAD rs760427398
- D83H (p.Asp83His), Ensembl rs1596076126
- D83N (p.Asp83Asn), cosmic curated COSV10034, Ensembl rs1596076126
- D83V (p.Asp83Val), NCI-TCGA Cosmic COSV5748, cosmic curated COSV57483, Ensembl rs2151551314, Variant assessed as somatic; moderate impact.
- L84P (p.Leu84Pro), Ensembl rs1596076114
- G85A (p.Gly85Ala), Ensembl rs2151551307
- G85R (p.Gly85Arg), rs1316240101, NCI-TCGA Cosmic COSV5747, cosmic curated COSV57472, gnomAD rs1316240101, REVEL 0.97, CADD 30.00, Uncertain significance, D-2-hydroxyglutaric aciduria 2
- L86F (p.Leu86Phe), Ensembl rs2151551302, REVEL 0.61, CADD 26.70
- L86P (p.Leu86Pro), Ensembl rs2151551300
- P87L (p.Pro87Leu), TOPMed rs1901008031
- P87S (p.Pro87Ser), cosmic curated COSV57482, Ensembl rs2151551296, REVEL 0.27, CADD 24.00
- N88K (p.Asn88Lys), gnomAD rs1236204052
- R89C (p.Arg89Cys), rs997901344, ClinGen CA274626561, cosmic curated COSV57476, ClinVar RCV000494115, REVEL 0.81, CADD 33.00, Uncertain significance, not provided
- R89H (p.Arg89His), rs371777275, ClinGen CA7733232, cosmic curated COSV57483, ClinVar RCV003516262, REVEL 0.81, CADD 29.60, Uncertain significance, D-2-hydroxyglutaric aciduria 2
- R89P (p.Arg89Pro), ESP rs371777275, ExAC rs371777275, gnomAD rs371777275, Uncertain significance
- D90E (p.Asp90Glu), Ensembl rs2151551292
- Q91H (p.Gln91His), Ensembl rs2151551290
- D93N (p.Asp93Asn), Ensembl rs1596076081
- D93Y (p.Asp93Tyr), Ensembl rs1596076081
- D94E (p.Asp94Glu), gnomAD rs1363662099, REVEL 0.55, CADD 25.10
- Q95* (p.Gln95Ter), Ensembl rs2151551282
- Q95H (p.Gln95His), Ensembl rs2151551281, REVEL 0.50, CADD 24.60
- V96A (p.Val96Ala), Ensembl rs2151551279
- V96D (p.Val96Asp), Ensembl rs2151551279
- V96L (p.Val96Leu), Ensembl rs2151551280, REVEL 0.39, CADD 25.60
- I98T (p.Ile98Thr), rs139512088, ClinGen CA7733230, cosmic curated COSV10588, ClinVar RCV001038725, REVEL 0.34, CADD 24.50, Uncertain significance, D-2-hydroxyglutaric aciduria 2
- A101T (p.Ala101Thr), Ensembl rs2151551274, REVEL 0.70, CADD 26.80
- A101V (p.Ala101Val), Ensembl rs2151551271, REVEL 0.55, CADD 28.30
- L102Q (p.Leu102Gln), Ensembl rs2151551266
- A103D (p.Ala103Asp), gnomAD rs1360419649, REVEL 0.88, CADD 29.80
- A103S (p.Ala103Ser), cosmic curated COSV10521, TOPMed rs1901007047
- A103T (p.Ala103Thr), TOPMed rs1901007047
- A103V (p.Ala103Val), gnomAD rs1360419649
- T104A (p.Thr104Ala), ExAC rs776827975, gnomAD rs776827975, REVEL 0.16, CADD 24.00
- T104N (p.Thr104Asn), 1000Genomes rs191685011, REVEL 0.48, CADD 25.10
- Y107C (p.Tyr107Cys), rs1596076050, ClinGen CA393802666, ClinVar RCV001373998, TOPMed rs1596076050, AlphaMissense 0.28, MetaLR 0.31, Uncertain significance, D-2-hydroxyglutaric aciduria 2
- S108N (p.Ser108Asn), ExAC rs773592372, gnomAD rs773592372, REVEL 0.12, CADD 8.62
- V109G (p.Val109Gly), 1000Genomes rs2151551241
- V109L (p.Val109Leu), Ensembl rs2151551246
- A110P (p.Ala110Pro), ESP rs368655225, ExAC rs368655225, TOPMed rs368655225, gnomAD rs368655225, REVEL 0.76, CADD 27.70
- A110S (p.Ala110Ser), ESP rs368655225, ExAC rs368655225, TOPMed rs368655225, gnomAD rs368655225
- A110T (p.Ala110Thr), NCI-TCGA TCGA novel, ESP rs368655225, ExAC rs368655225, TOPMed rs368655225, Variant assessed as somatic; moderate impact.
- A110V (p.Ala110Val), Ensembl rs2151551237
- C113* (p.Cys113Ter), Ensembl rs2151551231
- C113F (p.Cys113Phe), rs2505796605, ClinGen CA393802625, ClinVar RCV002637293, Uncertain significance, D-2-hydroxyglutaric aciduria 2
- A114P (p.Ala114Pro), Ensembl rs2151551229
- A114V (p.Ala114Val), Ensembl rs2151551228
- T115S (p.Thr115Ser), Ensembl rs1007176774, REVEL 0.73, CADD 26.50
- P118L (p.Pro118Leu), NCI-TCGA Cosmic COSV1003, Variant assessed as somatic; high impact.
- D119V (p.Asp119Val), gnomAD rs1280950562, REVEL 0.86, CADD 32.00
- E120D (p.Glu120Asp), 1000Genomes rs536071174, ExAC rs536071174, TOPMed rs536071174, gnomAD rs536071174, Likely benign
- E120G (p.Glu120Gly), Ensembl rs2151551220, REVEL 0.70, CADD 26.80
Public IDH2 analysis runs
- IDH2 analysis run — IDH2 (1,082 variants) — completed 2026-08-18